Max Müller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Max Müller has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Marie-Luise Winz
Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
5 shared publications - Kaushik Viswanathan Iyer
Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Mainz, 55128, Germany
3 shared publications - Lena Sophie Tittel
Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Mainz, 55128, Germany
3 shared publications Alina-Andrea Kraft
Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz , Staudingerweg 5, 5128 Mainz
1 shared publication- Alina-Andrea Kraft
Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Mainz, 55128, Germany
1 shared publication - Bram C. J. van der Eerden
Department of Internal Medicine, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5735-5748
Sex-specific regulation of angiogenin in Alzheimer’s disease
Alzheimer’s disease (AD) is a heterogeneous neurodegenerative disorder, highlighting the need to identify novel molecular regulators for effective treatment development. Angiogenin (ANG), a stress-responsive ribonuclease that inhibits apoptosis by generating 5′-tRNA fragments, is a candidate whose expression and regulation in AD is not understood. Here, we investigated ANG expression and regulation using AD cell and animal models, postmortem human brain tissue, and transcriptomic datasets ( n = 645). We found that ANG is dysregulated in AD in a sex-dependent manner, altering downstream levels of 5′-tiRNA Gly-GCC . Our analysis revealed female-specific molecular subtypes, absent in males: Subtype 1 featured low ANG levels with increased inflammation and neuronal death; subtype 2 exhibited higher ANG expression and intermediate pathology; subtype 3, marked by the highest ANG levels, showed reduced inflammation, slower cognitive decline, and extended survival. These findings position ANG as a key modulator of neuroinflammation and apoptosis in AD, highlighting its potential as a treatment strategy.
- 2 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5735-5748
Open AccessSex-specific regulation of angiogenin in Alzheimer’s disease
Alzheimer’s disease (AD) is a heterogeneous neurodegenerative disorder, highlighting the need to identify novel molecular regulators for effective treatment development. Angiogenin (ANG), a stress-responsive ribonuclease that inhibits apoptosis by generating 5′-tRNA fragments, is a candidate whose expression and regulation in AD is not understood. Here, we investigated ANG expression and regulation using AD cell and animal models, postmortem human brain tissue, and transcriptomic datasets ( n = 645). We found that ANG is dysregulated in AD in a sex-dependent manner, altering downstream levels of 5′-tiRNA Gly-GCC . Our analysis revealed female-specific molecular subtypes, absent in males: Subtype 1 featured low ANG levels with increased inflammation and neuronal death; subtype 2 exhibited higher ANG expression and intermediate pathology; subtype 3, marked by the highest ANG levels, showed reduced inflammation, slower cognitive decline, and extended survival. These findings position ANG as a key modulator of neuroinflammation and apoptosis in AD, highlighting its potential as a treatment strategy.
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (3)
Yeast elongation factor homolog New1 protects a subset of mRNAs from degradation by no-go decay
New1 is a homologue of the essential yeast translation elongation factor eEF3. Lack of New1 has been shown to induce ribosome queuing upstream of the stop codon on messenger RNAs (mRNAs) with specific C-terminal lysine and arginine codons. Here, we used ultraviolet crosslinking and analysis of complementary DNA (cDNA), long-read nanopore sequencing, and proteomics to address the consequences such queues have for the yeast cell. We show that these queues represent collisions, recognized by collision sensor Hel2, triggering mRNA degradation via canonical no-go decay (NGD). We identified 139 target mRNAs, on which decay is initiated by Cue2-mediated cleavage upstream of the stop codon. Compared to other collision-prone mRNAs, ending on the same C-terminal codons, these targets are characterized by stronger secondary structures upstream of the stop codon, longer queues, and stronger queuing signatures. Nanopore sequencing enabled characterization of NGD cleavage fragments across targets. Ultimately, NGD in the absence of New1 leads to downregulation of encoded proteins, including highly abundant and essential metabolic enzymes like Pgk1 and Gpm1, as well as translation elongation factors such as eEF1-alpha and eEF1-beta. We show that New1 protects such mRNAs from degradation by NGD and that NGD is a major determinant of the cold sensitive growth phenotype observed in NEW1 deletants.
- 22 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (3)
Open AccessYeast elongation factor homolog New1 protects a subset of mRNAs from degradation by no-go decay
New1 is a homologue of the essential yeast translation elongation factor eEF3. Lack of New1 has been shown to induce ribosome queuing upstream of the stop codon on messenger RNAs (mRNAs) with specific C-terminal lysine and arginine codons. Here, we used ultraviolet crosslinking and analysis of complementary DNA (cDNA), long-read nanopore sequencing, and proteomics to address the consequences such queues have for the yeast cell. We show that these queues represent collisions, recognized by collision sensor Hel2, triggering mRNA degradation via canonical no-go decay (NGD). We identified 139 target mRNAs, on which decay is initiated by Cue2-mediated cleavage upstream of the stop codon. Compared to other collision-prone mRNAs, ending on the same C-terminal codons, these targets are characterized by stronger secondary structures upstream of the stop codon, longer queues, and stronger queuing signatures. Nanopore sequencing enabled characterization of NGD cleavage fragments across targets. Ultimately, NGD in the absence of New1 leads to downregulation of encoded proteins, including highly abundant and essential metabolic enzymes like Pgk1 and Gpm1, as well as translation elongation factors such as eEF1-alpha and eEF1-beta. We show that New1 protects such mRNAs from degradation by NGD and that NGD is a major determinant of the cold sensitive growth phenotype observed in NEW1 deletants.
- Open Access
Jlp2 is an RQC complex-independent release factor acting on aberrant peptidyl-tRNA, protecting cells against translation elongation stress
Summary: Ribosome stalling results in aberrant nascent peptides attached to large ribosomal subunits after ribosome splitting. Proteasomal peptide degradation is canonically initiated by the Ribosome-associated Quality Control (RQC) complex, including K48-linked polyubiquitination by Ltn1 and Rqc1, and addition of non-templated ‘CAT tails’ by Rqc2 facilitates ubiquitination and promotes CAT tail-mediated degradation. Ubiquitinated peptides are released from tRNA by Vms1. Ubiquitination-independent processing of aberrant nascent peptides remains poorly understood. Here, we identify budding yeast Jlp2 as a factor in an RQC complex-independent mechanism that counteracts excessive CAT tailing and facilitates peptide release from the tRNA in the absence of Ltn1-mediated K48-linked ubiquitination. We characterize its ribosomal binding behavior and substrate preferences and identify residues in Jlp2 that are crucial for its function. We propose that Jlp2-mediated peptide release acts as a fail-safe for situations of RQC failure, or insufficiency, and for substrates without accessible ubiquitination-target lysines, to protect cells during ribosome stalling. Graphical
Open AccessJlp2 is an RQC complex-independent release factor acting on aberrant peptidyl-tRNA, protecting cells against translation elongation stress
Summary: Ribosome stalling results in aberrant nascent peptides attached to large ribosomal subunits after ribosome splitting. Proteasomal peptide degradation is canonically initiated by the Ribosome-associated Quality Control (RQC) complex, including K48-linked polyubiquitination by Ltn1 and Rqc1, and addition of non-templated ‘CAT tails’ by Rqc2 facilitates ubiquitination and promotes CAT tail-mediated degradation. Ubiquitinated peptides are released from tRNA by Vms1. Ubiquitination-independent processing of aberrant nascent peptides remains poorly understood. Here, we identify budding yeast Jlp2 as a factor in an RQC complex-independent mechanism that counteracts excessive CAT tailing and facilitates peptide release from the tRNA in the absence of Ltn1-mediated K48-linked ubiquitination. We characterize its ribosomal binding behavior and substrate preferences and identify residues in Jlp2 that are crucial for its function. We propose that Jlp2-mediated peptide release acts as a fail-safe for situations of RQC failure, or insufficiency, and for substrates without accessible ubiquitination-target lysines, to protect cells during ribosome stalling. Graphical
- 13 September 2023
- Published by Wiley in ChemBioChem
- Vol. 24 (20)
Cover Feature: Molecular Highway Patrol for Ribosome Collisions (ChemBioChem 20/2023)
- 13 September 2023
- Published by Wiley in ChemBioChem
- Vol. 24 (20)
Cover Feature: Molecular Highway Patrol for Ribosome Collisions (ChemBioChem 20/2023)
- Open Access
- 10 August 2023
- Published by Wiley in ChemBioChem
- Vol. 24 (20) , e202300264
Molecular Highway Patrol for Ribosome Collisions
During translation, messenger RNAs (mRNAs) are decoded by ribosomes which can stall for various reasons. These include chemical damage, codon composition, starvation, or translation inhibition. Trailing ribosomes can collide with stalled ribosomes, potentially leading to dysfunctional or toxic proteins. Such aberrant proteins can form aggregates and favor diseases, especially neurodegeneration. To prevent this, both eukaryotes and bacteria have evolved different pathways to remove faulty nascent peptides, mRNAs and defective ribosomes from the collided complex. In eukaryotes, ubiquitin ligases play central roles in triggering downstream responses and several complexes have been characterized that split affected ribosomes and facilitate degradation of the various components. As collided ribosomes signal translation stress to affected cells, in eukaryotes additional stress response pathways are triggered when collisions are sensed. These pathways inhibit translation and modulate cell survival and immune responses. Here, we summarize the current state of knowledge about rescue and stress response pathways triggered by ribosome collisions.
- 10 August 2023
- Published by Wiley in ChemBioChem
- Vol. 24 (20) , e202300264
Open AccessMolecular Highway Patrol for Ribosome Collisions
During translation, messenger RNAs (mRNAs) are decoded by ribosomes which can stall for various reasons. These include chemical damage, codon composition, starvation, or translation inhibition. Trailing ribosomes can collide with stalled ribosomes, potentially leading to dysfunctional or toxic proteins. Such aberrant proteins can form aggregates and favor diseases, especially neurodegeneration. To prevent this, both eukaryotes and bacteria have evolved different pathways to remove faulty nascent peptides, mRNAs and defective ribosomes from the collided complex. In eukaryotes, ubiquitin ligases play central roles in triggering downstream responses and several complexes have been characterized that split affected ribosomes and facilitate degradation of the various components. As collided ribosomes signal translation stress to affected cells, in eukaryotes additional stress response pathways are triggered when collisions are sensed. These pathways inhibit translation and modulate cell survival and immune responses. Here, we summarize the current state of knowledge about rescue and stress response pathways triggered by ribosome collisions.
- Open Access
- 15 June 2022
- Published by Elsevier in Bone Reports
- Vol. 16, 101379
Methylglyoxal affects human mesenchymal stem cell-derived osteoblast and adipocytes differentiation in vitro
- 15 June 2022
- Published by Elsevier in Bone Reports
- Vol. 16, 101379
Open AccessMethylglyoxal affects human mesenchymal stem cell-derived osteoblast and adipocytes differentiation in vitro